Closing EVAPORATE Outcomes for Vascepa Raise Eyebrows

Closing 18-month outcomes of the EVAPORATE trial point out icosapent ethyl (Vascepa) offers even elevated slowing of coronary plaque development when added to statins for sufferers with high triglyceride stages, but no longer all cardiologists are pleased. The peer became…